Ostensibly these data reflect positive-selection associated with RB1 loss and is consistent with the finding that RB1 loss occurs more frequently in metastatic advanced cancers of this type (e.g., prostate and breast) and is associated with poor outcome34,35. The gene discussed is RB1; the disease is cancer.